The value of proton therapy in managing prostate cancer is not yet defined. A recent study has reported promising long-term results for patients with localized prostate cancer who received proton therapy. However, results from ongoing clinical trials are required before determining the role of proton therapy for this indication.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Trofimov, A. et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int. J. Radiat. Oncol. Biol. Phys. 69, 444–453 (2007).
Vargas, C. et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70, 744–751 (2008).
Pan, H. Y. et al. Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate cancer. J. Clin. Oncol. 36, 1823–1830 (2018).
Xiang, M., Chang, D. T. & Pollom, E. L. Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy. Cancer 126, 3560–3568 (2020).
Suit, H. et al. Proton beams to replace photon beams in radical dose treatments. Acta. Oncol. 42, 800–808 (2003).
Takagi, M. et al. Proton therapy for localized prostate cancer: long-term results from a single-center experience. Int. J. Radiat. Oncol. Biol. Phys. https://doi.org/10.1016/j.ijrobp.2020.11.007 (2020).
Roach, M. 3rd et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 65, 965–974 (2006).
Hoppe, B. S. et al. Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer 120, 1076–1082 (2014).
Morris, W. J. et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 98, 275–285 (2017).
The authors declare no competing interests.
About this article
Cite this article
Bryant, C.M., Hoppe, B.S. Promising long-term results with proton therapy for localized prostate cancer. Nat Rev Urol 18, 137–138 (2021). https://doi.org/10.1038/s41585-021-00429-5